drugset / Trial / NCT04951349
Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.
Phase 2
Completed
85 enrolled
Turn Therapeutics
Gorgas Memorial Institute for Health Studies · collabHospital Modular - Covid-19 · collabHospital Santo Tomas · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2b clinical trial to evaluate the safety and efficacy of intranasal application of GX-03 as a treatment and prevention for COVID-19.
Timeline
- Start
- 2021-01-21
- Primary completion
- 2021-05-30
- Completion
- 2021-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BENZALKONIUM | Small molecule | 0.0065 % | Intranasal |